Celularity, Inc. (NASDAQ:CELU) Sees Large Growth in Short Interest

Celularity, Inc. (NASDAQ:CELU) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 483,285 shares, a growth of 26.6% from the December 15th total of 381,786 shares. Approximately 2.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 108,359 shares, the days-to-cover ratio is presently 4.5 days. Based on an average daily trading volume, of 108,359 shares, the days-to-cover ratio is presently 4.5 days. Approximately 2.1% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CELU. Acadian Asset Management LLC purchased a new position in Celularity during the 1st quarter worth $34,000. Valmark Advisers Inc. acquired a new position in shares of Celularity during the second quarter worth about $98,000. XTX Topco Ltd raised its holdings in Celularity by 106.4% during the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock worth $42,000 after purchasing an additional 11,057 shares in the last quarter. Bank of America Corp DE boosted its holdings in Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after purchasing an additional 35,023 shares in the last quarter. Finally, HB Wealth Management LLC acquired a new position in Celularity during the 3rd quarter worth approximately $84,000. Institutional investors and hedge funds own 19.02% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Celularity in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $6.00.

Celularity Trading Up 1.6%

CELU traded up $0.02 on Friday, reaching $1.31. The stock had a trading volume of 26,469 shares, compared to its average volume of 66,642. The company has a market cap of $37.31 million, a P/E ratio of -0.39 and a beta of 0.80. The business’s 50-day moving average price is $1.55 and its two-hundred day moving average price is $2.21. Celularity has a 12-month low of $1.00 and a 12-month high of $4.35.

Celularity (NASDAQ:CELU) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.62. The company had revenue of $5.28 million during the quarter.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.